Jazz Pharmaceuticals
🇮🇪Ireland
- Country
- 🇮🇪Ireland
- Ownership
- Public
- Employees
- 2.8K
- Market Cap
- $7B
- Introduction
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Court Upholds FDA's Approval of Avadel's Lumryz Over Jazz's Xywav in Orphan Drug Exclusivity Dispute
A U.S. District Court upheld the FDA's decision to approve Avadel's Lumryz, a once-nightly sodium oxybate formulation, for narcolepsy.